Technology News and Research

RSS

New resorbable beta-tricalcium phosphate bone void filler

Therics, Inc., a subsidiary of Tredegar Corporation, announced that it has received FDA clearance to market a new resorbable beta-tricalcium phosphate bone void filler device used to treat osseous defects of the skeletal system.

22 Mar 2004

DNA repair enzymes to fight cancer

The body has a set of DNA repair enzymes that clean up damage to the genome, to reduce potential problems. Many commonly used cancer chemotherapies work by alkylating DNA. However, the DNA repair enzymes are just as capable of repairing this alkylation as if it were damage from any other source, and so they act to overcome the effects of the therapy, reducing its effectiveness.

22 Mar 2004

Scientists identify genetic changes during infection by tuberculosis

Researchers at the Center for Biomedical Inventions at UT Southwestern Medical Center at Dallas have identified the genetic changes that Mycobacterium tuberculosis, the bacterium that causes tuberculosis, undergoes during infection of a living host.

22 Mar 2004

New Treatment for Chronic Head Pain

Dr. Levy pioneered a procedure known as supraorbital nerve stimulation or SOS, in which neurotransmitters are implanted into the forehead to block head pain. Tiny wires are burrowed under the skin until the precise location of pain is marked by a tingling response to electrical charge. The wires are kept in place for a week, and if pain is lessened and the patient is comfortable with the technology, neurotransmitters are surgically implanted under local anesthesia. The patient is able to control pain relief by manually adjusting the level of electrical stimulation through a hand held device.

22 Mar 2004

New drug to treat urinary tract infections, a step closer

Depomed, Inc. today announced top line results from the Phase III clinical trial of its Ciprofloxacin GR, an extended release formulation of ciprofloxacin HCl, which is used to treat urinary tract infections. The data confirmed Phase II results, demonstrating that Depomed's once-daily Ciprofloxacin GR eliminated the organisms responsible for urinary tract infections as effectively as twice-daily CIPRO(R), but with fewer gastrointestinal side effects, specifically fewer incidences of nausea and diarrhea.

22 Mar 2004

Information about Lasik eye surgery, a new technique to treat cataracts

Using an advanced microsurgical technology, called Aqualase(R), a New York eye surgeon is now able to use a procedure to essentially "wash" cataracts away. "By using Aqualase(R) to treat my cataract patients, I am able to dissolve the clouded lens with pulses of warm, naturally balanced salt water solution in order to 'wash away' the lens layer by layer," said Satish Modi, M.D., F.R.C.S. ( C ), a leading ophthalmic surgeon in Poughkeepsie.

22 Mar 2004

New surgical glove alleviates need for "double gloving"

A unique, high-sensitivity, double surgical glove that saves time and money will be debuted at the Association of Operating Room Nurses (AORN) Congress in San Diego, March 20-25. The glove was developed by Bio-Barrier Inc., an infection control technology company based in Los Angeles. The new glove features two separate layers originating from a single cuff at the wrist.

22 Mar 2004

Liverpool scientist presents chronic illness study to House of Commons

A social scientist from the University of Liverpool has visited the House of Commons to present preliminary findings of an innovative research project to MPs.

22 Mar 2004

Atrix Signs Feasibility Agreement for Development of Two New Compounds

Atrix Laboratories, Inc. has announced today that the company has signed a limited feasibility agreement with Aventis SA (NYSE: AVE) to begin preliminary research on two proprietary Aventis compounds formulated in Atrix's delivery technology, Atrigel®. The current agreement is specific for these compounds in an undisclosed therapeutic area.

22 Mar 2004

Pharmexa vaccine is designed to induce antibody responses against the HER-2 protein

Pharmexa presents data from the HER-2 Protein AutoVac™ breast cancer trial at a Conference in Hamburg Summary: Pharmexa is presenting data from the first clinical trial in USA with the HER-2 Protein AutoVac™ vaccine at the 4th European Breast Cancer Conference (EBCC) in Hamburg, Germany.

22 Mar 2004

MorphoSys Obtains Patents on Antibody Technologies

MorphoSys Obtains Additional U.S. Patents on Antibody Technologies MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) announced today that the U.S. Patent & Trademark Office has granted two new patents, which further strengthen the Company’s IP portfolio.

22 Mar 2004

Supercomputer to help the diagnosis of epilepsy, stroke, depression and other brain conditions

The University of Oregon, Electrical Geodesics, Inc. (EGI), and IBM have announced a new project that uses grid computing, Linux and IBM supercomputer technology to speed and improve the diagnosis of Epilepsy, stroke, depression and other brain conditions.

22 Mar 2004

Japanese study raises concerns for childhood health issues

The number of children suffering from mental disorders and health problems such as allergies and asthma has risen sharply over the past decade in this country. The United States and European countries are also facing the increasingly serious problems of premature births and childhood obesity, in addition to allergic reactions. Many experts say the rise in health problems involving children is related to the use of chemicals in our daily lives and the impact of medical treatment provided to the children's mothers.

22 Mar 2004

New optical glucose sensor could mean help for diabetics

Researchers at the University of California, Santa Cruz, have developed a novel optical glucose sensor that could be used to provide continuous monitoring of glucose levels in diabetics and hospitalized patients. Recently published studies showed that the sensor detects glucose under physiological conditions, giving a reversible fluorescent signal that changes intensity in response to changes in the concentration of glucose.

22 Mar 2004

£76 million research centre to make the UK a global centre of excellence for clinical imaging

GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.

22 Mar 2004

Drug Based on Brain Chemical Could End Narcolepsy and Insomnia

Researchers at UT Southwestern Medical Center at Dallas have discovered a potentially new avenue for treating human narcolepsy, and the work may also lead to more effective ways for insomniacs to boost their wakefulness during the daytime.

22 Mar 2004